PDCD1 and hepatocellular carcinoma: The combination of PD-1 inhibitors with the TGF-β1 receptor inhibitor, galunisertib, was evaluated in various pre-clinical models of HCC and resulted in the disruption of intra-tumor TGF-β signaling and the activation of anticancer immunity.